最新医学別冊 診断と治療のABC142 ウイルス性肝炎

出版社: 最新医学社
発行日: 2019-01-01
分野: 臨床医学:一般  >  雑誌
ISSN: 03708241
雑誌名:
特集: ウイルス性肝炎
電子書籍版: 2019-01-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

特記事項:
  • 「診断と治療のABC」シリーズは本号を以て休刊となります。

目次

  • 表紙
  • 目次
  • MAP 眼で見るウイルス性肝炎
  • 第1章 概念・疫学
  • ウイルス性肝炎の概念と分類
  • ウイルス性肝炎の疫学
  • 第2章 病理・病態生理
  • 肝炎ウイルスの種類
  • ウイルス性肝炎の発症機構
  • ウイルス性肝炎の病理像と組織分類
  • 肝炎ウイルス関連肝がんのがんゲノム変異と発がん機構
  • 慢性肝炎・肝硬変の病態と自然経過
  • 第3章 診断
  • 血液生化学検査, 肝炎ウイルスマーカー
  • 腫瘍マーカーと線維化・発がんリスクマーカー
  • 画像所見 : 急性肝炎, 慢性肝炎, 肝硬変
  • 第4章 B型肝炎
  • B型急性肝炎の疫学・自然経過
  • B型慢性肝炎・肝硬変の自然経過と予後
  • 治療ガイドライン
  • 核酸アナログ製剤
  • インターフェロン製剤
  • B型肝炎再活性化と対策
  • コラム B型肝炎完全排除を目指した薬剤の開発状況
  • 第5章 C型肝炎
  • C型急性肝炎
  • C型肝炎と糖脂質代謝
  • 治療ガイドライン
  • 直接作用型抗ウイルス薬 ( DAA ) による抗ウイルス療法
  • 薬剤耐性変異と再治療
  • 非代償性肝硬変の治療
  • ウイルス排除と肝発がんリスク
  • コラム 直接作用型抗ウイルス薬 ( DAA ) 治療とHBV再活性化
  • 第6章 経口肝炎 ( A型, E型肝炎 )
  • A型肝炎
  • E型肝炎
  • 第7章 肝疾患診療と行政, 病診連携
  • ウイルス性肝炎・肝硬変診療に関連する社会保障制度
  • 肝疾患診療連携拠点病院と地域的・全国的な肝炎診療連携ネットワーク
  • B型肝炎母子感染防止対策
  • コラム ウイルス肝炎の受検・受療に向けた取組み : 肝炎医療コーディネーター
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・疫学

P.17 掲載の参考文献
1) Henning K J, et al : A community-wide outbreak of hepatitis A : risk factors for infection among homosexual and bisexual men. Am J Med 99 : 132-136, 1995.
2) Brown G R, et al : Hepatitis A epidemic in the elderly. South Med J 95 : 826-833, 2002.
3) Chang M H, et al : Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period : clinical and liver histologic studies. Hepatology 8 : 374-377, 1988.
4) Lok A S, et al : A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 8 : 1130-1133, 1988.
5) Lok A S, et al : Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 : 1839-1843, 1987.
10) Inagaki Y, et al : A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis E in Liver Transplant Recipients in Japan. EBioMedicine 2 : 1607-1612, 2015.
P.26 掲載の参考文献
1) World Health Organization : Hepatitis C, Hepatitis B. (Global Alert and Response, 2002), World Health Organization, Geneva, 2002.
2) World Health Organization : Global hepatitis report. 2017.
3) The Polaris Obervatory HCV Collaborators : Global prevalance and genotype distribution of hepatitis C virus infection 2015 : a modelling study. Lancet Gastroenterol Hepatol 2 : 161-176, 2017.
4) Oza N, et al : Current activities and future directions of comprehensive hepatitis control measures in Japan : The supportive role of the Hepatitis Information Center in building a solid foundation. Hep Res 47 (6) : 487-496, 2017.
6) 厚生労働科学研究費補助金 肝炎等克服政策研究事業 平成26年度「急性感染も含めた肝炎ウイルス感染状況・長期経過と治療導入対策に関する研究」研究報告書. 2015.
9) Tanaka J, et al : Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology 54 (4) : 185-195, 2011.
10) 相崎英樹 : 感染症サーベイランスの現状把握, 厚生労働科学研究費補助金 (肝炎等克服政策研究事業) 肝炎ウイルス感染状況と感染後の長期経過に関する研究 (代表 : 田中純子) 平成29年度分担研究報告書, p59-60. 2018.
11) 相崎英樹 : 1999年から2013年に感染症法に基づき届出された急性C型肝炎の疫学解析, 厚生労働科学研究費補助金 (肝炎等克服政策研究事業) 急性肝炎も含めた肝炎ウイルス感染状況・長期経過と治療導入対策に関する研究 (代表 : 田中純子) 平成26年度分担研究報告書, p55-58. 2015.
12) Uchida S, et al : Incidence rates of hepatitis C virus infection among blood donors in Japan : a nationwide retrospective cohort study. Transfusion (in press).
13) Tanaka J, et al : Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology 51 (1) : 33-41, 2008.
14) 平成29年度厚生労働科学研究費補助金 肝炎等克服政策研究事業肝炎ウイルス感染状況と感染後の長期経過に関する研究総括・研究報告書 (田中純子), p207-222, 2018.

第2章 病理・病態生理

P.34 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017年8月.
2) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第62版). 2018年10月.
3) 日本肝臓学会編 : 肝臓専門医テキスト (改訂第2版). 南江堂, 東京, 2016.
4) 新ウイルス性肝炎学 (最新の基礎・臨床研究情報). 日本臨床社, 大阪, 2015.
P.42 掲載の参考文献
2) Guidotti L G et al : Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 : 23-61, 2006.
6) Horner S M, et al : Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19 : 879-888, 2013.
7) Hiet M S : Control of temporal activation of hepatitis C virus-induced interferon response by domain 20f nonstructural protein 5A. J Hepatol 63 : 829-837, 2015.
21) Cheon H : IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. Embo J 32 : 2751-2763, 2013.
22) Chen L : Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 : 1437-1444, 2005.
31) Feng Z : A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496 : 367-371, 2013.
35) Wang H, et al : Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX 3 : implications for immune evasion. PLoS Pathog 6 : e1000986, 2010.
36) Liu Y H : Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol 89 : 2287-2300, 2015.
37) Chen J L : Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 57 : 470-482, 2013.
38) Wei C : The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185 : 1158-1168, 2010.
39) Lutgehetmann M : Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 140 : 2074-2083, 2011.
44) Moal V, et al : Chronic hepatitis E virus infection is specifically associated with an interferon-related transcriptional program. J Infect Dis 207 : 125-132, 2013.
48) Thimme R : CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 : 68-76, 2003.
50) Shin E C : Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141 : 686-695, 2011.
52) Sung P S, et al : CD8+ T-Cell responses in acute hepatitis C virus infection. Front Immunol 5 : 266, 2014.
53) Lechner F : Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 : 1499-1512, 2000.
54) Thimme R : Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 : 1395-1406, 2001.
55) Shin E C : The frequency of CD127+ hepatitis C virus (HCV) -specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol 87 : 4772-4777, 2013.
56) Bowen D G, et al : Mutational escape from CD8+ T cell immunity : HCV evolution, from chimpanzees to man. J Exp Med 201 : 1709-1714, 2005.
61) Smyk-Pearson S : Functional suppression by FoxP3+CD4+CD25high regulatory T cells during acute hepatitis C virus infection. J Infect Dis 197 : 46-57, 2008.
65) Rehermann B : The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181 : 1047-1058, 1995.
72) Manangeeswaran M : Binding of hepatitis A virus to its cellular receptor 1 inhibits T-regulatory cell functions in humans. Gastroenterology 142 : 1516-1525, 2012.
75) Golden-Mason L : Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83 : 9122-9130, 2009.
77) Bengsch B : Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6 : e1000947, 2010,
79) Lee J, et al : T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw 10 : 120-125, 2010.
81) Kroy D C : Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146 : 550-561, 2014.
84) Fuller M J : Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 110 : 15001-15006, 2013.
85) Gardiner D : A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8 : e63818, 2013.
86) Bengsch B, et al : Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61 : 1212-1219, 2014.
92) Fisicaro P : Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143 : 1576-1585, 2012.
93) Kurktschiev P D : Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med 211 : 2047-2059, 2014.
100) Boettler T : Tcells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 : 7860-7867, 2005.
101) Franceschini D : PD-L1 negatively regulates CD4+CD25+Foxp3+ T regs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 119 : 551-564, 2009.
P.56 掲載の参考文献
1) Neil D. Theise N D, et al : 6-Viral Hepatitis. In : Macsween's Pathology of the Liver (7th edition). p372-415, Science Direct 2018.
2) 市田文弘, 他 : 慢性肝炎の肝組織診断基準-新犬山分類. 中外医学社, 東京, 1996.
3) Bedossa P, et al : An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 : 289-293, 1996.
9) Issa R, et al : Apoptosis of hepatic stellate cells : involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 : 548-557, 2001.
11) Calvaruso V, et al : Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 155 : 411-421, e414, 2018.
P.65 掲載の参考文献
8) Killela P J, et al : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110 : 6021-6026, 2013.
15) Brechot C, et al : Presence of integrated hepatitis B Virus DNA sequences in cellUlar DNA of human hepatocellular carcinoma. Nature 286 : 533-535, 1980.
P.71 掲載の参考文献
1) Guidotti L G, et al : Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 1 : 23-61, 2006.
2) Iannacone M, et al : HBV pathogenesis in animal models : recent advances on the role of platelets. J Hepatol 46 : 19-26, 2007.
4) Tutteleman J S, et al : Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47 : 451-460, 1986.
5) Xu L, et al : Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice. Hepatology 59 : 443-452, 2014.
7) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン第3版. 2017.
14) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepaol 67 : 933-939, 2017.
15) Llach J, et al : Prognostic value of arterial pressure, endogeneous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology 94 : 482-487, 1988.

第3章 診断

P.79 掲載の参考文献
P.87 掲載の参考文献
1) 日本肝臓学会 : 肝癌診療ガイドライン2017年版. 2017.
2) Ishii M, et al : Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95 : 1036-1040, 2000.
5) Kumada T, et al : High-sensitivity Lens culinaris agglutinin-reactive aipha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 49 : 555-563, 2014.
6) 日本肝臓学会 : B型肝炎治療ガイドライン. 2017.
7) 日本肝臓学会 : C型肝炎治療ガイドライン. 2018.
8) 泉並木, 他編 : 肝疾患診療に役立つ肝線維化評価テキスト. 文光堂, 東京, 2017.
14) Shiratori Y, et al : Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 132 : 517-524, 2000.
16) Oze T, et al : Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 12 : 1186-1195, 2014.
20) Nahon P, et al : Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 152 : 142-156. e142, 2017.
P.94 掲載の参考文献

第4章 B型肝炎

P.100 掲載の参考文献
4) 国立感染症研究所 : 感染症発生動向調査年別報告数一覧 (全数把握 五類) -2016-. <https://www.niid.go.jp/niid/ja/survei/2085-idwr/ydata/7312-report-ja2016-30.html>
6) 山田典栄, 他 : 首都圏におけるB型急性肝炎の実態と変遷GenotypeAに焦点をあてて. 肝臓 49 (12) : 553-559, 2008.
8) Matsuura K, et al : Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47 (5) : 1476-1483, 2009.
9) 吉澤浩二, 他 : ウイルス肝炎 診断/予防/治療第2版. p21. 文光堂, 東京, 2002.
13) Bodsworth N J, et al : The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163 (5) : 1138-1140, 1991.
P.107 掲載の参考文献
2) 田中純子, 他 : 我が国におけるB型肝炎の疫学-国際比較を含めて. 日臨 69 : 327-334, 2011.
6) Lin C L, et al : Natural history of acute and chronic hepatitis B : the roles of HBV genotypes and mutants. Best Prac Res Clin Gastroenterol 31 : 249-255, 2017.
7) Ito K, et al : Risk factors for long-term persistence of serum HBs antigen following acute B virus infection in Japanese adults. Hepatology 59 : 89-97, 2014.
8) McMahon J : The natural history of chronic hepatitis B virus infection, Hepatology 49 : S45-S55, 2009.
11) lloeje U H, et al : Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 : 678-686, 2006.
13) 田中靖人, 他 : B型肝炎ウイルスコア関連抗原 (HBcrAg) 測定法の基礎的・臨床的検討, モダンメディア 54 : 347-352, 2008.
14) Rokuhara A, et al : Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen ; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10 : 324-330, 2003.
15) Ando Y, et al : Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos (t) ide analog treatment. Hepatol Res 48 : E240-E251, 2018.
P.117 掲載の参考文献
1) Chang M H, et al : Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Eng J Med 336 (26) : 1855-1859, 1997.
2) 日本肝臓学会, 肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017.
P.130 掲載の参考文献
2) Ono A, et al : Long-term continuous entecavir therapy in nucleos (t) ide-naive chronic hepatitis Bpatients. J Hepatol 57 : 508-514, 2012.
4) Kumada H, et al : Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos (t) ide analogs. Hepatol Res 47 : 1032-1041, 2017.
6) Murakami E, et aHmplications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 59 : 3563-3569, 2015.
7) Agarwal K, et al : Twenty-eight day safety, anti-viral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62 : 533-540, 2015.
10) 日本肝臓学会肝炎診療ガイドライン作成委員会 : B型肝炎治療ガイドライン (第3版). 2017.
12) Hara T, et al : Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos (t) ide-naive chronic hepatitis B patients. J Viral Hepat 21 : 802-808, 2014.
13) Suzuki F, et al : Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol 2018 [Epub ahead of print].
14) Agarwal K, et al : 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68 : 672-681, 2018.
15) Buti M, et al : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 : 196-206, 2016.
16) Matsumoto A, et al : Combinational use of hepatitis B viral antigens predicts responses to nucleos (t) ide analogue/peg-interferon sequential therapy. J Gastroenterol 53 : 247-257, 2018,
17) Bourliere M, et al : Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos (t) ide analogue therapy versus nucleos (t) ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA : a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2 : 177-188, 2017.
18) Fontana R J : Side effects of long-term oral anti-viral therapy for hepatitis B. Hepatology 49 (Suppl 5) : 185-195, 2009.
24) Hosaka T, et al : Combined hepatitis B core-related antigen and surface antigen levels predict hepatocellular carcinoma development in patients treated with nucleos (t) ide analogues. Hepatology 62 (suppl) : 1193A, 2015.
P.139 掲載の参考文献
1) 肝炎ガイドライン作成委員会 : B型肝炎治療ガイドライン (第3版). 日本肝臓学会, 2017.
2) Croagh M N C, et al : Genotypes and viral variants in chronic hepatitis B : A review of epidemiology and clinical relevance. World J Hepatol 7 : 289-303, 2015.
5) Matsumoto A, et al : Combination of hepatitis B viral antigens and DNA for prediction of relaps after discontinuation of nucleos (t) ide analog in patients with chronic hepatitis B. Hepatol Res 42 : 139-149, 2012.
6) Tanaka E, et al : Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res 44 : 818-824, 2014.
7) Serfaty L, et al : sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone : results of a pilot study. Hepatology 34 : 573-577, 2001.
8) Matsumoto A, et al : Combinational use of hepatitis B viral antigens predicts responses to ucleos (t) ide analogue/peg-interferon sequential therap. J Gastroenterol 53 : 247-257, 2018.
9) Murata K, et al : Induction of IFN-λ3 as an addi-tional effect of nucleotide, not nucleoside, analogues : a new potential target for HBV infection. GUT 67 : 362-371, 2018.
10) Marcellin P, et al : Combination of tenofovir Disoproxil fumarate and peginterferon a-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastrenterology 150 : 134-144, 2016.
11) Marcellin P, et al : Predictors of response to tenofovir disproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol THer 44 : 957-966, 2016.
P.148 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドラン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017年8月 <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b>
2) 坪内博仁, 他 : 免疫抑制・化学療法により発症するB型肝炎対策 : 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療標準化に関する研究」班合同報告. 肝臓 50 : 38-42, 2009.
5) 持田智, 他 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2016年) : 平成29年度全国調査. 厚生労働省科学研究費補助金 (難治性疾患等政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」平成29年度総括・分担研究報告書 p85-104, 2018.
6) Galbraith R M, et al : Fulminant hepatic failure in leukaemia and Nchoriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2 : 528-530, 1975.
7) Wands J R, et al : Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative
8) Lok A S, et al : Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 : 182-188, 1991.
9) Kempinska A, et al : Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient : case report and review of the literature. Clin Infect Dis 41 : 1277-1282, 2005.
11) 木村公則, 他 : 造血幹細胞移植後におけるB型肝炎ウイルス再活性化の実態および予防に関する多施設共同臨床研究. 固形がんにおけるB型肝炎ウイルス再活性化. 厚生労働科学研究費補助金肝炎等克服実用化研究事業 (肝炎等克服緊急対策事業), 「がん化学療法及び免疫抑制療法中のB型肝炎再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」班, 平成24~26年度総合研究報告書. P47-51, 2015.
15) 池田公史, 他 : 固形がんにおけるB型肝炎ウイルス再活性化厚生労働科学研究費補助金肝炎等克服実用化研究事業 (肝炎等克服緊急対策事業), 「がん化学療法及び免疫抑制療法中のB型肝炎再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」班, 平成24~26年度総合研究報告書. P31-34, 2015.
21) 持田智, 他 : 免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎ウイルス再活性化の実態解明と対策法の確立」全体研究 (平成23年度). 厚生労働科学研究費補助金肝炎等克服緊急対策事業 (肝炎分野), 「免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎再活性化の実態解明と対策法の確立」班, 平成23年度研究報告書 pp1-32, 2012.

第5章 C型肝炎

P.155 掲載の参考文献
1) Maheshwari A, et al : Acute hepatitis C. Lancet 26 : 321-322, 2008.
2) Tanaka E, et al : Natural history of acute hepatitis C J Gastroenterol Hepatol 15 : E97-104, 2000.
3) Ge D, et al : Genetic variation in IL 28 B predicts hepatitis C treatmentinduced viral clearance. Nature 461 : 399-401, 2009.
6) 相崎英樹, 他 : わが国における急性ウイルス肝炎の動向. 医のあゆみ 262 : 1215-1220, 2017.
7) 野村秀幸 : C型急性肝炎の治療IFN治療開始のタイミングは? 肝胆膵 57 : 925-929, 2008.
8) Nomura H, et al : Short-term interferon-alfa therapy for acute hepatitis C : arandomized controlled trial. Hepatology 39 : 1213-1219, 2004.
9) 八橋弘, 他 : C型肝炎 (インターフェロン, 化学療法). 臨と微生物 35 : 703-709, 2008.
10) Kamal S M, et al : Peginterferon alfa-2b therapy in acute hepatitis C : impact of onset of therapy on sustained virologic response. Gastroenterology 130 : 632-638, 2016.
P.162 掲載の参考文献
2) Hui J M, et al : Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125 : 1695-1704, 2003.
4) Shintani Y, et al : Hepatitis C virus infection and diabetes : direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 : 840-848, 2004.
5) Alan R, et al : Insulin signalling and the regulation of glucose and Iipid metabolism. Nature 414 (6865) : 799-806, 2001.
7) Tsutsumi T, et al : Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304 : 415-424, 2002.
13) Bach N, et al : The histological features of chronic hepatitis C and autoimmune chronic hepatitis : a comparative analysis. Hepatology 15 : 572-577, 1992.
16) Moriishi K, et al : Critical role of PA28gamma in hepatitis C virusassociated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 104 : 1661-1666, 2007.
18) Foretz M, et al : ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19 (5) : 3760-3768, 1999.
P.169 掲載の参考文献
1) Yamada I, et al : Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat 19 : e112-119, 2012,
7) 日本肝臓学会, 肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第6.2版). 2018. <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c>
8) Kumada H, et al : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53 : 566-575, 2018.
P.178 掲載の参考文献
2) Ogasawara N, et al : Serial changes in liver stiffness and controlled attenuation parameter following drect-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol 90 : 313-319, 2018.
6) Kanwal F, et al : Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 153 : 996-1005. e1, 2017.
7) 肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第6.2版). 2018.
9) El-Sherif O, et al : Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154 : 2111-2121. e8, 2018.
10) Chen G, et al : Hepadtis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents : A systematic review and meta-analysis. Hepatology 66 : 13-26, 2017.
18) Toyoda H, et al : Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2018 [Epub ahead of print].
P.188 掲載の参考文献
1) 肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第6.2版). <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c>
5) Krishnan P, et al : Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother 62 (2) : pii : e02217-17, 2018.
7) Kumada H, et al : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53 : 566-575, 2018.
P.196 掲載の参考文献
1) McCaughan G W, et al : Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD≧15). Aliment Pharmacol Ther 47 (3) : 401-411, 2018.
2) Chanton M, et al : Ledipasvir and Sofbsbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 149 (3) : 649-659, 2015.
6) Younossi Z M, et al : Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis : an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 1 (2) : 122-132, 2016.
10) Taniyama O, et al : Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b. Hepatol Res 2018 [Epub ahead of print].
13) Verma N, et al : Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis. Hepatol Commun 2 (1) : 16-20, 2017.
15) European Association for the Study of the Liver (EASL) : EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65 (1) : 146-181, 2016.
17) Cox-North P, et al : Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 1 (3) : 248-255, 2017.
18) El-Sherif O, et al : Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154 (8) : 2111-2121. e8, 2018.
19) Cheung M C M, et al : Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (4) : 741-747, 2016.
23) Lens S, et al : Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology 153 (5) : 1273-1283. e1, 2017.
P.205 掲載の参考文献
1) 日本肝癌研究会追跡調査委員会 : 第19回全国原発性肝癌追跡調査報告 (2006-2007). 肝臓 57 (1) : 45-73, 2016.
2) Kasahara A, et al : Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 11 (2) : 148-156, 2004.
3) Yoshida H, et al : Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma : National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. Ann Intern Med 131 (3) : 174-181, 1999.
6) Tateyama M, et al : Alpha-fetoprotein above normal levels as a risk factor for the development of epatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 46 (1) : 92-100, 2011.
9) Morgan R L, et al : Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : a meta-analysis of observational studies. Ann Intern Med 158 (5) : 329-337, 2013.
10) Watanabe S, et al : Cancer preventive effect of pegylated interferon alpha-2b plus ribavirin in a real-life clinical setting in Japan : PERFECT interim analysis. Hepatol Res 41 (10) : 955-964, 2011.
14) Tanaka A, et al : Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with anti-viral therapy in patients with chronic hepatitis C. World J Gastroenterol 13 (39) : 5180-5187, 2007.
15) Akuta N, et al : Amino acid substitu-tions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 83 (6) : 1016-1022, 2011.
16) Asahina Y, et al : Alpha-fetoprotein levels after interferon therapy and risk of hepatocar-cinogenesis in chronic hepatitis C. Hepatology 58 (4) : 1253-1262, 2013.
22) Innes H, et al : The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response : role of the treatment regimen. J Hepatol 68 : 646-654, 2018.
23) Ioannou G N, et al : HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 68 : 25-32, 2018.
28) Ooka Y, et al : Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatol Int 2018 (in press).
29) Ioannou G N, et al : Development of models estimating the risk of hepatocellular carcinoma after antiviral treatmellt for hepatitis C. J Hepatol 2018 [Epub ahead of print].
P.208 掲載の参考文献

第6章 経口肝炎 ( A型, E型肝炎 )

P.214 掲載の参考文献
1) 神田達郎, 他 : A型肝炎の最近の動向. 消化器・肝臓内科 4 (2) : 2018.
4) Yan J, et al : Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan. Hepatol Res 42 (10) : 974-981, 2012.
7) Feng Z, et al : Apathogenic picornavirus acquires an envelope by hijacking cellular mem. branes. Nature 496 (7445) : 367-371, 2013.
8) 高橋和明, 他 : 血中のA型肝炎ウイルス粒子には脂質膜エンベロープが存在する. 肝臓 54 (6) : 396-398, 2013.
20) 神田達郎 : A型肝炎の現状とトピックス. Med Pract 34 (5) : 787-789, 2017.
23) Mena G, et al : Hepatitis B and A vaccination in HIV-infected adults : A review. Hum Vaccin Immunother 11 (11) : 2582-2598, 2015.
24) Kim M J, et al : Identification of transfusion-transmitted hepatitis A through postdonation information in Korea : results of an HAV lookback (2007-2012). Vox Sang 2018 [Epub ahead of print].
26) 神田達郎, 他 : 乾燥A型肝炎ワクチン. 肝胆膵 61 (6) : 1095-1099, 2010.
27) Jung Y M, et al : Atypical manifestations of hepatitis A infection : a prospective, multicenter study in Korea. J Med Virol 82 (8) : 1318-1326, 2010.
P.222 掲載の参考文献
1) 安藤文英, 他 : 国内で感染し発症した散発性E型急性肝炎と思われる1邦人例. 肝臓 35 : 560-565, 1994.
7) Miyashita K, et al : Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan : Zoonotic food-borne transmission of hepatitis E virus and public health concerns. Hepatol Res 42 : 870-878, 2012.
8) Tamada Y, et al : Consumption of wild boar linked to cases of hepatitis E. J Hepatology 40 : 869-870, 2004.
11) Li T C, et al : Detection of hepatitis E virus RNA from the bivalve Yamato-Shijimi (Corbicula japonica) in Japan. Am J Trop Med Hyg 76 : 170-172, 2007.
13) Arankalle V A, et al : Human and swine hepatitis Eviruses from Western India belong to different genotypes. J Hepatol 36 : 417-425, 2002.
14) 阿部敏紀, 他 : 本邦に於けるE型肝炎ウイルス感染の統計学的・疫学的・ウイルス学的特徴 : 全国集計254例に基づく解析. 肝臓 47 : 384-391, 2006.
15) 国立感染症研究所HP. IDWR速報データ
16) Takeda H, et al : Anationwide survey for prevakence of hepatitis E virus antibody in qualified blood donors in Japan. Vox San 99 : 307-313, 2010.
17) Matsubayashi K, et al : Acase of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-bome route. Transfusion 48 : 1368-1375, 2008.
19) Miyoshi M, et al : Chronic Hepatitis E Infection in a Persistently Immunosuppressed Patient Unable to Be Eliminated after Ribavirin Therapy. Intern Med 55 : 2811-2817, 2016.

第7章 肝疾患診療と行政, 病診連携

P.231 掲載の参考文献
P.236 掲載の参考文献
1) 都道府県における肝炎検査後肝疾患診療体制に関するガイドライン 全国C型肝炎診療懇談会報告書 (平成19年1月26日). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/03.html>
2) 肝疾患診療体制の整備について (通知, 健発第0419001号平成19年4月19日). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-24.pdf>
3) 肝炎対策基本法 (平成21年12月4日法律九十七号, 平成22年1月1日施行, 平成25年12月13日改正). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/hourei_01.html>
4) 肝炎対策の推進に関する基本的な指針 (平成23年5月16日策定, 平成28年6月30日改正). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-27.pdf>
5) 国立国際医療研究センター肝炎情報センターホームページ. <www.kanen.ncgm.go.jp/index.htmi>
P.243 掲載の参考文献
2) 白木和夫 : わが国におけるB型肝炎母子感染防止の経緯とuniversal vaccinationの必要性について. 小児感染免疫 21 (2) : 149-157, 2009.
3) Okada K, et al : Hepatitis B surface antigen in the serum of infants after deliver from asymptomatic carrier mothers. J Pediatr 87 (3) : 360-363, 1975.
4) Okada K, et al : eantigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294 (14) : 746-749, 1976.
5) Shiraki K, et al : Acute hepatitis B in infants born tocarrier mothers with the antibody to hepatitis Beantigen. J Pediatr 97 (5) : 768-770, 1980.
6) 白木和夫, 他 : B型肝炎ウイルスの垂直感染-そのnatural historyと予防. 医のあゆみ 118 : 536-545, 1981.
7) Shiraki K : Vertical transmission of hepatitis B virus and its prevention in Japan. In : Viral Hepatitis and Liver Disease (Nishioka K, et al, eds) p530-532. Springer-Verlag, Tokyo, 1994.
8) 白木和夫 : B型肝炎母子感染防止対策の追跡調査および効果判定に関する研究. 厚生省心身障害研究「小児の心身障害・疾患の予防と治療に関する研究」 (主任研究者 : 柳澤信義) 分担研究 平成8年度研究報告書, 1997.
9) Emini E A, et al : Production and immunological analysis recombinant hepatitis B vaccine. J Infect 13 (Suppl. A) : 3-9, 1986.
11) 小松陽樹, 他 : Genotype AのB型肝炎ウイルスキャリア妊婦に対するgenotype C由来の抗原を用いたHBワクチンの母子感染予防効果. 肝臓 56 (12) : 675-677, 2015.
12) 乾あやの, 他 : B型肝炎母子感染防止不成功例の解析. 肝臓 51 (8) : 457-459, 2010.

最近チェックした商品履歴

Loading...